Tracking Prescription Chemotherapy "Monthly Chemotherapy Rx Tracker: TRx..."

Research evidence excerpt

Tracking Prescription Chemotherapy "Monthly Chemotherapy Rx Tracker: TRx..."

Global Research

13 May 2026ab

Tracking Prescription Chemotherapy Equities

AmericasMonthly Chemotherapy Rx Tracker: TRx Scripts

Growth +11.6% Y/Y In April Healthcare

Kevin Caliendo

Analyst

kevin.caliendo@ubs.com

Monthly Chemotherapy Rx Tracker: We track a basket of the most prescribed +1-212-713 3630

chemotherapy drugs on a monthly basis as of the end of April. On a y/y TRx basis, April

Andrea Alfonso

increased by +11.6 % up from +10.9% in 1Q26 but down compared to +15.1% in

4Q25 and similar to +11.8% in Q3 25. Similarly, on a y/y NRx basis, the basket of drugs andrea.alfonso@ubs.com

rose +12.3% in April vs. +12.7% in 1Q26, vs. +11.3% in 4Q25 and +6.9% y/y in 3Q25. +1-212-713 1342

Within our coverage, greater use of oncology drugs could be negative for MCOs. By

contrast, more oncology scripts bode well for mix at COR and MCK, given their leverage

to oncology distribution. As it relates to EVH, the impact is more nuanced with the

company's exposure linked to site of care (Part B), payor (Medicare/Medicaid) and

whether the magnitude of utilization is priced in within EVH’s specific contracts with

customers. Management noted that embedded FY26 oncology utilization is expected to

remain largely in line with FY25 (approximately 11% - 12%), reflecting stable trends, per

commentary on the 1Q26 earnings call. Separately, we track prescription utilization via

IQVIA and the source estimates a -0.1% decline in total Rx data in April from y/y calendar

changes vs. a +1.7% impact in March.

Figure 1: Chemotherapy Drugs quarterly NRx Y/Y Figure 2: Chemotherapy Drugs quarterly TRx Y/Y

Chemo thera Y

Chemo thera py Dr uarte

Rx Y/ Y ugs q rly T Rx Y/

py D rugs qua

ly N

rter

Source: UBS Research.